Publications by Oncolines Scientists on ResidenceTimer™, QuickScout™

  • Jang et al. (2023) Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor. Cancer Chemotherapy and Pharmacology 91, 491-499.
  • Kooijman et al. (2022) Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Frontiers in Oncology, 12:953013.
  • Grobben et al. (2020) Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158. Journal of Structural Biology: X, 4:100014.
  • Uitdehaag et al. (2019) Combined cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017. Molecular Cancer Therapeutics, 18 (2):470-481.
  • Uitdehaag et al. (2017) Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity. Journal of Molecular Biology, 429:2211-2230.
  • Willemsen-Seegers et al. (2017) Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance. Journal of Molecular Biology, 429:574-586.
  • Libouban et al. (2017) Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines. Oncotarget, 8 (24):38309–38325. (collaboration with Netherlands Cancer Institute)
  • Uitdehaag et al. (2014) Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use. PLoS ONE, 9 (3):e92146.

Publications by Oncolines Scientists on Arginase Gold™, NFK Green™

  • Grobben et al. (2021) Targeting indoleamine 2,3-dioxygenase in cancer models using the novel small molecule inhibitor NTRC 3883-0. Frontiers in Immunology, section Cancer Immunity and Immunotherapy, 11:609490. (Collaboration with Radboud University Medical Center)
  • Perez-Pardo et al. (2021) Pharmacological validation of TDO as a target for Parkinson’s disease. The FEBS Journal, 288:4311-4331. (Collaboration with Utrecht University)
  • Grobben et al. (2020) High-Throughput Fluorescence-Based Activity Assay for Arginase-1. SLAS Discovery, 25 (9):1018-1025.
  • Seegers et al. (2014) High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes. Journal of Biomolecular Screening, 19 (9):1266-1274.

References by our Clients to ResidenceTimer™

  • Khameneh et al. (2024) The bacterial lysate OM-85 engages Toll-like receptors 2 and 4 triggering an immunomodulatory gene signature in human myeloid cells. Mucosal Immunology, in press (Affiliation: IBR Bellinzona, OM Pharma, Oncolines)
  • Zalini et al. (2022) BAL0891: a novel dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division. Poster presentation at AACR Annual Meeting 2022. (Affiliation: Basilea Pharmaceutica International Ltd.)
  • Wentsch et al. (2017) Optimized Target Residence Time: Type 1½ Inhibitors for p38a MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine. Angewandte Chemie International Edition, 56 (19):5363-5367. (Affiliations: University of Tübingen, NTRC)

References by our Clients to NFK Green™

  • Pei et al. (2019) TDO2 and IDO1 inhibitors, International Patent Application WO 2019/005559. (Affiliation: Genentech, Inc.)
  • Pei et al. (2019) TDO2 and IDO1 inhibitors, International Patent Application WO 2019/006047. (Affilitation: Genentech, Inc.)
  • Liu et al. (2019) Crystal of tricyclic acid, International Patent Application WO 2019/034139. (Affiliation: Tianqing Pharmaceutical Group Co., Ltd.)
  • Garapaty et al. (2017) Small molecule modulators to understand the role of IDO1 and TDO2 in cance. Cancer Research, 77 (13 Supplement):5578-5578. (Affiliation: Jubilant Biosys Ltd.)